Isla Pharmaceuticals specializes in drug repurposing to develop antiviral therapeutics targeting tropical diseases, with a focus on dengue fever. Their lead candidate, ISLA-101, aims to provide effective treatment options for patients suffering from this infectious disease.
Funding
$2.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Dengue fever, a mosquito-borne viral disease prevalent in tropical regions, lacks specific and effective antiviral treatments, resulting in significant morbidity and burden on healthcare systems. Existing treatments primarily focus on managing symptoms, leaving a critical need for therapeutics that directly target the virus and reduce disease severity.
Solution
Island Pharmaceuticals is focused on repurposing existing drugs to develop antiviral therapeutics for treating tropical infectious diseases, with a primary focus on dengue fever. Their lead drug candidate, ISLA-101, is being developed as a targeted antiviral treatment to combat the dengue virus. By repurposing drugs, Island Pharmaceuticals aims to accelerate the development timeline and provide a more effective treatment option for patients suffering from dengue fever. The company's approach seeks to address the unmet need for specific antiviral therapies, potentially reducing the severity and duration of the illness.
Target Audience
The primary target audience includes patients infected with the dengue virus, healthcare providers in tropical regions, and public health organizations seeking effective treatment options for dengue fever.
Features
- ISLA-101: Lead drug candidate targeting dengue fever, currently in clinical development.
- Drug repurposing strategy: Utilizing existing drugs with known safety profiles to accelerate development.
- Focus on antiviral therapeutics: Developing treatments that directly target the dengue virus.
- Clinical program: Advancing ISLA-101 through clinical trials to demonstrate efficacy and safety.